Streetbeat News

Earnings

XCUR

Exicure (NASDAQ:XCUR) reported a significant improvement in its Q2 earnings per share (EPS), with losses narrowing to $(0.07) from $(0.68) in the same period last year, representing an 89.71% increase.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:15 pm

BTTR

Better Choice Co (AMEX:BTTR) reported Q2 adjusted EPS of $(1.02), a significant improvement from $(4.40) YoY. However, sales decreased by 18.93% to $8.54M from $10.54M YoY.

Portfolio Pulse from totan@benzinga.com

August 13, 2024 | 8:15 pm

CURI

CuriosityStream (NASDAQ:CURI) reported Q2 2024 GAAP EPS of $(0.04), beating the $(0.06) estimate, but sales of $12.395M missed the $12.423M estimate. Sales decreased by 12.07% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:15 pm

KRRO

Korro Bio (NASDAQ:KRRO) reported a Q2 EPS of $(2.43), missing the analyst consensus estimate of $(2.40) by 1.25%. This represents a 96.19% improvement over the $(63.83) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:14 pm

TNON

Tenon Medical (NASDAQ:TNON) reported Q2 2024 GAAP EPS of $(1.02), beating the estimate of $(1.08). However, sales of $901K missed the $909.5K estimate. Sales increased by 21.27% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:14 pm

JSDA

Jones Soda (OTC:JSDA) reported a Q2 GAAP EPS of $(0.02), a 100% decrease from $(0.01) YoY. Sales increased by 48.92% to $7.16M from $4.81M YoY.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:13 pm

NKTX

Nkarta (NASDAQ:NKTX) reported a Q2 EPS loss of $(0.34), beating the analyst consensus estimate of $(0.47) by 27.66%. This represents a 50% improvement over the $(0.68) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:13 pm

CTSO

CytoSorbents (NASDAQ:CTSO) reported Q2 2024 GAAP EPS of $(0.08), beating the $(0.10) estimate. Sales were $9.895M, surpassing the $9.678M estimate and showing a 5.03% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:13 pm

TENX

Tenax Therapeutics (NASDAQ:TENX) reported a Q2 2024 adjusted EPS of $(1.83), beating the analyst consensus estimate of $(1.99) by 8.04%.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:13 pm

RVYL

RYVYL shares are trading lower following a Q2 earnings and revenue miss.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:13 pm